As such, we hypothesized that, by blocking the interaction of extracellular CIRP with its receptor, treatment with C23 should decrease the activation of leukocytes and EC and, thus, attenuate sepsis severity and mortality. This evidence concerns the gene CIRBP and Sepsis.